Autologous peripheral blood stem cell transplantation using Thiotepa, Carboplatin and Etoposide conditioning in patients with relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)

Autologous peripheral blood stem cell transplantation using Thiotepa, Carboplatin and Etoposide conditioning in patients with relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT) - Autologous peripheral blood stem cell transplantation using Thiotepa, Carboplatin and Etoposide conditioning in patients with relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026084

Enrollment

Registered

2017-05-01

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)

Interventions

thiotepa 300mg/m2/day*3days carboplatin area under curve 7 mg/ml*min/day *3days etoposide 250mg/m2/day*3days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 medulloblastoma, PNET, ATRT 2 refractory or relapsed 3 performance status is 0 to 2 4 Ejection Fraction is more than or equal to 50 percent 5 24hour creatinine clearance is more than or equal to 40ml/min/1.73m2 6 neutrophil count is more than or equal to 1*10 3/microL 7 platelet count is more than or equal to 50*10 3/microL 8 total bilirubin level is less than or equal to (5*upper limit of age reference value) mg/dL 9 AST(GOT) is less than or equal to (5*upper limit of age reference value) U/L 10 ALT(GPT) is less than or equal to (5*upper limit of age reference value) U/L 11 SpO2 is more than or equal to 95 percent 12 storage autologous peripheral blood stem cell

Exclusion criteria

Exclusion criteria: 1 active double cancer 2 active infection needed systemic therapy 3 body temperature more than or equal to 38 degrees C 4 in pregnancy, breastfeeding, strong possibility of pregnancy 5 positive in HBs antigen, HBV-DNA, HCV antibody 6 positive in HIV antibody(no measurement is OK) 7 inadequate for other reason by doctor's assessment

Design outcomes

Primary

Measure	Time frame
day100 mortality	—

Countries

Japan

Contacts

Public ContactHideki Muramatsu

Nagoya University Graduate School of Medicine Pediatrics

hideki-muramatsu@med.nagoya-u.ac.jp052-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026